Structure-based design of molecular cancer therapeutics

Trends in Biotechnology

Volumn 27, Issue 5, 2009, Pages 315-328

  van Montfort, Rob L M ^a   Workman, Paul ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCL-2 FAMILIES; CANCER DRUGS; CANCER THERAPEUTICS; DESIGN APPROACHES; DRUG DISCOVERIES; HISTONE DEACETYLASES; MOLECULAR CHAPERONES; OPTIMAL APPLICATIONS; PI3 KINASE; POLY POLYMERASE; PROTEIN KINASE; PROTEIN-PROTEIN INTERACTIONS; SMALL-MOLECULE INHIBITORS; STRUCTURAL INFORMATIONS; STRUCTURE-BASED; STRUCTURE-BASED DRUG DESIGNS; TARGET SELECTIONS; VIRTUAL SCREENINGS;

LEAD COMPOUNDS; TARGETS;

DESIGN;

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN MDM2; PROTEIN P53;

CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 64749110949     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2009.02.003     Document Type: Review

References (122)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
3. Workman P. Genomics and the second golden era of cancer drug development. Mol. Biosyst. 1 (2005) 17-26
4. Collins I., and Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2 (2006) 689-700
5. Walker I., and Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8 (2009) 15-16
6. Workman P., and de Bono J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr. Opin. Pharmacol. 8 (2008) 359-362
7. Congreve M., et al. Structural biology and drug discovery. Drug Discov. Today 10 (2005) 895-907
8. Scapin G. Structural biology and drug discovery. Curr. Pharm. Des. 12 (2006) 2087-2097
9. Blundell T.L., et al. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361 (2006) 413-423
10. Nienaber V.L., et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 18 (2000) 1105-1108
11. Rees D.C., et al. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3 (2004) 660-672
12. Hartshorn M.J., et al. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48 (2005) 403-413
13. Fink T., et al. Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew. Chem. Int. Ed. Engl. 44 (2005) 1504-1508
14. In: Jahnke W., and Erlanson D.A. (Eds). Fragment-Based Approaches in Drug Discovery (2006), Wiley-VCH
15. Hopkins A.L., et al. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9 (2004) 430-431
16. Hajduk P.J., and Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6 (2007) 211-219
17. Erlanson D.A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol. 17 (2006) 643-652
18. Congreve M., et al. Recent developments in fragment-based drug discovery. J. Med. Chem. 51 (2008) 3661-3680
19. Manning G., et al. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
20. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 (2002) 309-315
21. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 7 (2002) 601-611
22. Noble M.E., et al. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
23. Liao J.J.-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50 (2007) 409-424
24. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
25. Marsden B.D., and Knapp S. Doing more than just the structure-structural genomics in kinase drug discovery. Curr. Opin. Chem. Biol. 12 (2008) 40-45
26. Ghose A.K., et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J. Med. Chem. 51 (2008) 5149-5171
27. Benson C., et al. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br. J. Cancer 92 (2005) 7-12
28. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
29. Pao W., et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13306-13311
30. Weinstein I.B., and Joe A. Oncogene addiction. Cancer Res. 68 (2008) 3077-3080
31. Ward W.H., et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48 (1994) 659-666
32. Stamos J., et al. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277 (2002) 46265-46272
33. Yun C.-H., et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11 (2007) 217-227
34. Yun C.H., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2070-2075
35. Wood E.R., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2004) 6652-6659
36. Knighton D.R., et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253 (1991) 407-414
37. Caldwell J.J., et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J. Med. Chem. 51 (2008) 2147-2157
38. Yap T.A., et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8 (2008) 393-412
39. Garcia-Echeverria C., and Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27 (2008) 5511-5526
40. Donald A., et al. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J. Med. Chem. 50 (2007) 2289-2292
41. Gassel M., et al. Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol. 329 (2003) 1021-1034
42. Breitenlechner C.B., et al. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 48 (2005) 163-170
43. Davies T.G., et al. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol. 367 (2007) 882-894
44. Saxty G., et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem. 50 (2007) 2293-2296
45. Halilovic E., and Solit D.B. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr. Opin. Pharmacol. 8 (2008) 419-426
46. Krengel U., et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 62 (1990) 539-548
47. Gibbs J.B., and Oliff A. Pharmaceutical research in molecular oncology. Cell 79 (1994) 193-198
48. Konstantinopoulos P.A., et al. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6 (2007) 541-555
49. Ohren J.F., et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11 (2004) 1192-1197
50. Nagar B., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
51. Schindler T., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
52. Nolen B., et al. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15 (2004) 661-675
53. Hubbard S.R., et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 (1994) 746-754
54. Mol C.D., et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
55. Wan P.T.C., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
56. Heron N.M., et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 1320-1323
57. Tokarski J.S., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66 (2006) 5790-5797
58. Shah N.P., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
59. O'Hare T., et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65 (2005) 4500-4505
60. Domin J., and Waterfield M.D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 410 (1997) 91-95
61. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
62. Zhao L., and Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 27 (2008) 5486-5496
63. Walker E.H., et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6 (2000) 909-919
64. Stephens L., et al. Phosphoinositide 3-kinases as drug targets in cancer. Curr. Opin. Pharmacol. 5 (2005) 357-365
65. Huang C.-H., et al. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 318 (2007) 1744-1748
66. Knight Z.A., et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125 (2006) 733-747
67. Folkes A.J., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51 (2008) 5522-5532
68. Hayakawa M., et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg. Med. Chem. 14 (2006) 6847-6858
69. Raynaud F.I., et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67 (2007) 5840-5850
70. Guillard S., et al. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 8 (2009) 443-453
71. Apsel B., et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4 (2008) 691-699
72. Balakin K.V., et al. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer. Agents Med. Chem. 7 (2007) 576-592
73. Finnin M.S., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
74. Somoza J.R., et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12 (2004) 1325-1334
75. Miller T.A., et al. Histone deacetylase inhibitors. J. Med. Chem. 46 (2003) 5097-5116
76. Tikhe J.G., et al. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J. Med. Chem. 47 (2004) 5467-5481
77. Zaremba T., and Curtin N.J. PARP inhibitor development for systemic cancer targeting. Anticancer. Agents Med. Chem. 7 (2007) 515-523
78. Lord C.J., and Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8 (2008) 363-369
79. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 37 (1998) 3893-3900
80. Canan Koch S.S., et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. 45 (2002) 4961-4974
81. Plummer R., et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14 (2008) 7917-7923
82. Pearl L.H., et al. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410 (2008) 439-453
83. Workman P., et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 1113 (2007) 202-216
84. Prodromou C., et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 (1997) 65-75
85. Stebbins C.E., et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 (1997) 239-250
86. Roe S.M., et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42 (1999) 260-266
87. Wright L., et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 11 (2004) 775-785
88. Cheung K.M., et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 3338-3343
89. Sharp S.Y., et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 67 (2007) 2206-2216
90. Dymock B.W., et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 48 (2005) 4212-4215
91. Sharp S.Y., et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6 (2007) 1198-1211
92. Brough P.A., et al. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 51 (2008) 196-218
93. Eccles S.A., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68 (2008) 2850-2860
94. Smith J.R., and Workman P. Targeting the cancer chaperone HSP90. Drug Discov. Today: Therapeutic Strategies 4 (2007) 219-227
95. Kato M., et al. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 15 (2007) 992-1004
96. Arkin M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr. Opin. Chem. Biol. 9 (2005) 317-324
97. Wells J.A., and McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450 (2007) 1001-1009
98. Vogelstein B., et al. Surfing the p53 network. Nature 408 (2000) 307-310
99. Lane D.P., and Hupp T.R. Drug discovery and p53. Drug Discov. Today 8 (2003) 347-355
100. Kussie P.H., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (1996) 948-953
101. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
102. Grasberger B.L., et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48 (2005) 909-912
103. Ding K., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 49 (2006) 3432-3435
104. Shangary S., et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3933-3938
105. Domling A. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?. Curr. Opin. Chem. Biol. 12 (2008) 281-291
106. Juin P., et al. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim. Biophys. Acta 1644 (2004) 251-260
107. Berg T. Small-molecule inhibitors of protein-protein interactions. Curr. Opin. Drug Discov. Dev. 11 (2008) 666-674
108. Petros A.M., et al. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644 (2004) 83-94
109. Petros A.M., et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9 (2000) 2528-2534
110. Sattler M., et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275 (1997) 983-986
111. Shoemaker A.R., et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14 (2008) 3268-3277
112. Petros A.M., et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 49 (2006) 656-663
113. Oltersdorf T., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
114. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
115. Park C.M., et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 51 (2008) 6902-6915
116. Tse C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68 (2008) 3421-3428
117. Danilewicz J.C., et al. Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence. J. Med. Chem. 45 (2002) 2432-2453
118. Weigelt J., et al. Structural genomics and drug discovery: all in the family. Curr. Opin. Chem. Biol. 12 (2008) 32-39
119. Dorsam R.T., and Gutkind J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7 (2007) 79-94
120. Li S., et al. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol. 27 (2005) 1329-1339
121. Hopkins A.L., et al. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16 (2006) 127-136
122. Hartshorn M.J. AstexViewer: a visualisation aid for structure-based drug design. J. Comput. Aided Mol. Des. 16 (2002) 871-881